99Tc‑MDP treatment for the therapy of rheumatoid arthritis, choroidal neovascularisation and Graves' ophthalmopathy (Review)

Wu,Qian; Ni,Yang; Yang,Qingrui; Sun,Hongsheng

doi:10.3892/br.2016.609

99Tc‑MDP treatment for the therapy of rheumatoid arthritis, choroidal neovascularisation and Graves' ophthalmopathy (Review)

Authors:
- Qian Wu
- Yang Ni
- Qingrui Yang
- Hongsheng Sun
View Affiliations

Affiliations: Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: February 23, 2016 https://doi.org/10.3892/br.2016.609
Pages: 400-402

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Technetium 99 conjugated with methylene diphosphonate, which is an anti‑inflammatory drug, can inhibit macrophage infiltration and downregulate a number of proinflammatory cytokines, such as tumor necrosis factor‑α and interleukin‑1β. Recently, numerous studies have indicated that it could improve rheumatoid arthritis (RA) activity by upregulating the frequency of peripheral γδ T cells and cluster of differentiation CD4+CD25+Foxp3+ Tregs, affecting the serum cytokine environment, inhibiting osteoclast formation and reducing the concentrations of rheumatoid factor‑immunoglobulin M (IgM)/IgG/IgA. As well, it may have a therapeutic role for choroidal neovascularisation (CNV) and Graves' ophthalmopathy (GO). Therefore, it will be a valuable choice in the treatment of RA, CNV and GO.

View Figures

View References

1	Lai K, Xu L, Jin C, Wu K, Tian Z, Huang C, Zhong X and Ye H: Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) inhibits experimental choroidal neovascularization in vivo and VEGF-induced cell migration and tube formation in vitro. Invest Ophthalmol Vis Sci. 52:5702–5712. 2011. View Article : Google Scholar : PubMed/NCBI
2	Choi JK, Kim SW, Kim DS, Lee JY, Lee S, Oh HM, Ha YS, Yoo J, Park PH, Shin TY, et al: Oleanolic acid acetate inhibits rheumatoid arthritis by modulating T cell immune responses and matrix-degrading enzymes. Toxicol Appl Pharmacol. 290:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
3	Favalli EG, Becciolini A and Biggioggero M: Structural integrity versus radiographic progression in rheumatoid arthritis. RMD Open. 1(Suppl 1): e0000642015. View Article : Google Scholar : PubMed/NCBI
4	Meednu N, Zhang H, Owen T, Sun W, Wang V, Cistrone C, Rangel-Moreno J, Xing L, Med B and Anolik JH: A link between B cells and bone erosion in rheumatoid arthritis: Receptor activator of nuclear factor kappa-B ligand production by memory B cells. Arthritis Rheumatol. Nov 10–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
5	Owens GM: Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment. Am Health Drug Benefits. 8:354–360. 2015.PubMed/NCBI
6	Magyari L, Varszegi D, Kovesdi E, Sarlos P, Farago B, Javorhazy A, Sumegi K, Banfai Z and Melegh B: Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. World J Orthop. 5:516–536. 2014. View Article : Google Scholar : PubMed/NCBI
7	Rosado-de-Castro PH, de Lopes Souza SA, Alexandre D, da Barbosa Fonseca LM and Gutfilen B: Rheumatoid arthritis: Nuclear Medicine state-of-the-art imaging. World J Orthop. 5:312–318. 2014. View Article : Google Scholar : PubMed/NCBI
8	Al-Nahain A, Jahan R and Rahmatullah M: Zingiber officinale: A Potential Plant against Rheumatoid Arthritis. Arthritis. 2014:1590892014. View Article : Google Scholar : PubMed/NCBI
9	Scarno A, Perrotta FM, Cardini F, Carboni A, Annibali G, Lubrano E and Spadaro A: Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis. World J Orthop. 5:328–335. 2014. View Article : Google Scholar : PubMed/NCBI
10	Sonomoto K, Yamaoka K and Tanaka Y: An approach to bone and cartilage repair of rheumatoid arthritis by mesenchymal stem cells. J UOEH. 36:141–146. 2014.(In Japanese). View Article : Google Scholar : PubMed/NCBI
11	Su D, Shen M, Gu B, Wang X, Wang D, Li X and Sun L: 99 Tc-methylene diphosphonate improves rheumatoid arthritis disease activity by increasing the frequency of peripheral γδ T cells and CD4⁺ CD25⁺ Foxp3⁺ Tregs. Int J Rheum Dis. Jan 28–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
12	Ji Y, Huo X and Zhang H: Technetium 99Tc methylenediphosphonate inhibits osteoclast formation from PBMCs in patients with rheumatoid arthritis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 34:684–688. 2009.(In Chinese). PubMed/NCBI
13	Gong W, Dou H, Liu X, Sun L and Hou Y: Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis. Clin Exp Pharmacol Physiol. 39:886–893. 2012. View Article : Google Scholar : PubMed/NCBI
14	Huang A, Yu L and Shen L: Effect of technetium-99 conjugated with methylene diphosphonate on IgM-RF, IgG-RF and IgA-RF. J Huazhong Univ Sci Technolog Med Sci. 23:266–268. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wu YG, Ma QL and Liu GF: Effect of 99Tc-MDP on cytokine production by peripheral blood mononuclear cells of patients with rheumatoid arthritis. Hunan Yi Ke Da Xue Xue Bao. 27:173–175. 2002.(In Chinese). PubMed/NCBI
16	Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG, Lanzetta P, Chen Y and Tufail A: Myopic choroidal neovascularisation: Current concepts and update on clinical management. Br J Ophthalmol. 99:289–296. 2015. View Article : Google Scholar : PubMed/NCBI
17	Li T, Aredo B, Zhang K, Zhong X, Pulido JS, Wang S, He YG, Huang X, Brekken RA and Ufret-Vincenty RL: Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. Invest Ophthalmol Vis Sci. 56:7137–7145. 2015. View Article : Google Scholar : PubMed/NCBI
18	Weber ML and Heier JS: Choroidal Neovascularization Secondary to Myopia, Infection and Inflammation. Dev Ophthalmol. 55:167–175. 2016. View Article : Google Scholar : PubMed/NCBI
19	Nagai N, Ju M, Izumi-Nagai K, Robbie SJ, Bainbridge JW, Gale DC, Pierre E, Krauss AH, Adamson P, Shima DT, et al: Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability. Am J Pathol. 185:2534–2549. 2015. View Article : Google Scholar : PubMed/NCBI
20	Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, et al: Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 156:468–477.e2. 2013. View Article : Google Scholar : PubMed/NCBI
21	Bahn RS: Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 88:1939–1946. 2003. View Article : Google Scholar : PubMed/NCBI
22	Wei H, Guan M, Qin Y, Xie C, Fu X, Gao F and Xue Y: Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. Endocr J. 61:1087–1092. 2014. View Article : Google Scholar : PubMed/NCBI
23	Hahn E, Laperriere N, Millar BA, Oestreicher J, McGowan H, Krema H, Gill H, DeAngelis D, Hurwitz J, Tucker N, et al: Orbital radiation therapy for Graves' ophthalmopathy: Measuring clinical efficacy and impact. Pract Radiat Oncol. 4:233–239. 2014. View Article : Google Scholar : PubMed/NCBI
24	Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA and Gorman CA: The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol. 120:511–517. 1995. View Article : Google Scholar : PubMed/NCBI
25	Burch HB and Wartofsky L: Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev. 14:747–793. 1993. View Article : Google Scholar : PubMed/NCBI
26	Perros P, Crombie AL and Kendall-Taylor P: Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 42:45–50. 1995. View Article : Google Scholar : PubMed/NCBI
27	Zang S, Ponto KA and Kahaly GJ: Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 96:320–332. 2011. View Article : Google Scholar : PubMed/NCBI
28	Prummel MF and Wiersinga WM: Immunomodulatory treatment of Graves' ophthalmopathy. Thyroid. 8:545–548. 1998. View Article : Google Scholar : PubMed/NCBI
29	Mou P, Jiang LH, Zhang Y, Li YZ, Lou H, Zeng CC, Wang QH, Cheng JW and Wei RL: Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis. PLoS One. 10:e01395442015. View Article : Google Scholar : PubMed/NCBI
30	Yan SX, Wang Y, Peng GJ, Lu XP and Fu Y: Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves' ophthalmopathy. Nucl Med Commun. 32:142–146. 2011. View Article : Google Scholar : PubMed/NCBI
31	Pan W, Tan T, Wang Q and Zheng J: Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 19:300–301, 323. 2002.(In Chinese). PubMed/NCBI